Normalisation of Tissue Factor Pathway Inhibitor Activity after Glycaemic Control Optimisation in Type 1 Diabetic Patients

Mercedes Rigla; Jose Mateo; Jordi Fontcuberta; Juan Carlos Souto; Alberto de Leiva; Antonio Pérez

doi:10.1055/s-0037-1614000

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(02): 223-227
DOI: 10.1055/s-0037-1614000

Review Article

Schattauer GmbH

Normalisation of Tissue Factor Pathway Inhibitor Activity after Glycaemic Control Optimisation in Type 1 Diabetic Patients

Authors

Mercedes Rigla

²From the Department of Endocrinology and Nutrition, Universitat Autònoma de Barcelona, Spain
Jose Mateo

¹Department of Haematology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Spain
Jordi Fontcuberta

¹Department of Haematology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Spain
Juan Carlos Souto

¹Department of Haematology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Spain
Alberto de Leiva

²From the Department of Endocrinology and Nutrition, Universitat Autònoma de Barcelona, Spain
Antonio Pérez

²From the Department of Endocrinology and Nutrition, Universitat Autònoma de Barcelona, Spain

Abstract

Summary

Increased plasma concentrations of various markers of endothelial damage have been observed in type 1 diabetic patients, particularly in those with microangiopathy. Objective. To evaluate the effect of nearnormalisation of glycaemic control on different markers of endothelial injury involved in haemostasis in poorly-controlled type 1 diabetic patients. Material and Methods. TFPI, thrombomodulin (TM), plasminogen activator inhibitor, tissue-type plasminogen activator and von Willebrand factor were measured in 14 poorly-controlled type 1 diabetic patients free of diabetes-related complications (8 men, 6 women; mean age 29.8 ± 9.9 years) before (baseline) and after 3 months of intensive therapy and in 14 sex-, age-and BMI-matched control subjects. Results. After a mean follow-up of 107 ± 49 days (56-210), Hb A_1c decreased from 11.2 ± 2.3 to 6.7 ± 0.7% (p <0.0001). TFPI activity at baseline was higher than in the control group (126.9 ± 34 vs 92.0 ± 13%, p <0.005) and decreased after good glycaemic control was achieved (p <0.005), becoming similar to that in the control group (91.0 ± 16.5%). The TFPI descent correlated with the variations observed in HbA_1c (p <0.05; r = 0.54). TM levels at baseline were significantly higher than in the control group (42.3 ± 9.1 vs 29.00 ± 10.9; p <0.005) and did not change. The remaining parameters studied were similar between patients and controls and did not change after glycaemic optimisation. Conclusions. Optimisation of glycaemic control normalises the increased activity of TFPI but not the higher TM levels observed in poorly-controlled type 1 diabetic patients without chronic complications.

Key words

Type 1 diabetes - endothelial markers - TFPI - glycaemic control

Full Text

References

References
1 Stern DM, Esposito C, Gerlach H, Gerlach M, Ryan J, Handley D, Nawroth P. Endothelium and regulation of coagulation. Diabetes Care 1991; 14 (Suppl. 01) 160-6.
2 Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet. 1975 01. (7922): 1430 (Letter).
3 Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
4 Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-17.
5 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1990; 63: 157-62.
6 Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, Den Ottolander GJH. Von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 1991; 40: 971-6.
7 Carmassi F, Morale M, Puccetti R, de Negri F, Monzani F, Navalesi R, Mariani G. Coagulation and fibrinolytic system impairment in insulin-dependent diabetes mellitus. Thromb Res 1992; 67: 643-54.
8 Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-8.
9 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of Kunitz type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
10 Sandset PM. Tissue factor pathway inhibitor (TFPI) – an update. Haemostasis 1996; 26: 154-65.
11 Sandset PM, Abilgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
12 Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996; 19: 441-5.
13 Leurs PB, van Oerle R, Wolffenbuttel BHR, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 1997; 77: 472-6.
14 Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995; 44: 80-4.
15 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
16 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
17 Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7.
18 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
19 Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture: delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985; 34: 621-7.
20 National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-59.
21 Lipid Research Clinic Program. Manual of laboratory operations, lipid and lipoprotein analysis. In: Hainline A, Karon J, Lippel K. (eds). (2nd). National, Heart, Lung and Blood Institute. Bethesda, MD: (US Government Printing Office No 1982-361-132:678). HEW Publication No. (NIH): 75-628 (revised).
22 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
23 Vukovich TC, Schernthaner G, Knöbl PN, Hay U. The effect of nearormoglycaemic control on plasma factor VII/von Willebrand factor and fibrin degradation products in insulin-dependent diabetic patients. J Clin Endocrinol Metab 1989; 69: 84-9.
24 Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-20.
25 Sandset PM, Lund H, Norseth J, Ose L, Abilgaard U. Treatment with HMG-CoA reductase inhibitor in hypercholesterolaemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1991; 11: 138-45.
26 Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-25.
27 Cella G, Vettor R, Sbarai A, Rossi E, Rampin E, Macor C, Mussap M, Plebani M, Luzzato G, Girolami A. Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: effect of hyperinsulinemia. Semin Thromb Hemost 1997; 23: 129-34.
28 Takano S, Kimura S, Ohdoma S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
29 Sumida Y, Wada H, Fujii M, Mori Y, Nakasaki T, Shimura M, Hiyoyama K, Yano Y, Deguchi K, Shiku H, Adachi Y. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coag Fib 1997; 08: 303-7.
30 Reverter JL, Reverter JC, Tàssies D, Rius F, Monteagudo J, Rubiés-Prat J, Escolar G, Ordinas A, Sanmartí A. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: A prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997; 56: 93-9.
31 Esposito C, Gerlach H, Brett J, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
32 Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 01 8636. 461-3.
33 Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994; 43: 426-9.